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Introduction 
Pluronic P94 unimers (P94) are amphiphilic tri-block copolymers of 
poly(ethylene oxide) and poly(propylene exide) (PEO-PPO-PEO) (Fig 1a) 
with high in vivo stability and relatively long circulation times. Due to 
the enhanced permeability and retention (EPR) effect, P94 can 
accumulate in the tumor tissue and therefore be potentially used as 
drug carrier. For various macromolecules it has been shown that 
following intravenous (IV) administration (Fig 1b) , limited tumor 
accumulation occurs versus undesired high liver uptake and clearance 
via the mononuclear phagocyte system. Intratumoral (IT) administration 
(Fig 1c) might overcome this limitation by avoiding the systemic 
circulation and therefore improving the retention in the tumor.  
 
Aim of the study  
In this study we compared IT versus IV administration routes of 
radiolabeled P94 in terms of biodistribution profiles and tumor 
accumulation and retention over time in a mouse tumor model.  
 
 
 
 
 
 
 
 
 
 
Material and Methods 
H69 tumors were grown subcutaneously for approximately 3 weeks in 
Balb/c nude mice (N=20).  
P94 were modified by adding an -NH2 teminal, a DTPA chelator and 
labeled with 111In reaching a lebeling efficiency of 96%. 111In-DTPA-P94 
unimers were injected in tumor-bearing mice following two injection 
routes:  
• IV: N=8, 0.2 mg/mouse, ~ 10 MBq/animal 
• IT: N=8, 0.1 mg/mouse, ~ 5 MBq/animal  
For a negative control in IT condition, 111In-DTPA (200 pmol/mouse 
~3MBq) was injected in 4 tumor bearing mice.  
Molecular SPECT/CT imaging was performed at different time points 
post injection (pi): early (30 min or 4 h pi), intermediate (24 h pi), late  
time points (48 h pi).  
Ex vivo biodistribution was determined in isolated organs at 48 h and 
96 h pi. 
 
Results 
SPECT/CT images of 111In-DTPA-P94 after IV injection  (Fig 2a-c) show 
sustained accumulation in the liver, and little uptake in the tumor, 
which is also confirmed  by the ex vivo biodistribution (Fig 2d).  
After IT injection both the SPECT/CT images and  ex vivo 
biodistribution shows that  tumor has elevated retention while liver and 
off-target organs show a limited uptake (Fig 2e-i) 
 
 
 
 
 
Different injection routes  of  111In-DTPA-P94 depicts discordant 
retention in critical organs, namely tumor and liver (Fig 3a).  
Ex vivo biodistribution, at two different time points indicates the 
general trend of each organs to reduce the retention over time (Fig 2d 
and 2i). The  retention of 111In-DTPA-P94 over time was estimated by 
the calculation of tumor to tissue ratio (TTR) (Fig 3 b).  
For both injection routes, although the effect is more visible after IT 
injection, the TTR increases. This finding suggest that there is a 
generalized trend of retention of the traced in the tumor, in contrast 
with a progressive clearance in other organs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
IV injection of 111In-DTPA-P94 resulted in limited tumor uptake, 
whereas IT administration substantially increased the uptake in the 
tumor. The minimal involvement of off-target tissue, including liver, 
and the tracer retention over time especially for IT administration, 
confirmed the potential of 111In-DTPA-P94 to be used as a carrier for 
therapeutic radionuclides.   
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Fig 1. Schematic rapresentation of radiolabeled tracer and injection routes  (a) Schematic representation of 
111In-DTPA-P94 pluronics; (b) IV injection in the tail vein which provide systemic circulation of tracer and passive 
targeting in the tumor; (c) IT injection is carried out injecting directly in the tumor core allowing for local 
retention and low systemic involvement 
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Fig 2. In vivo SPECT/CT  imaging and ex vivo biodistribution of H69 tumor bearing mice after IV or IT 
administration of  111In-DTPA-P94 unimers. (a-c) Whole body SPECT/CT imaging  of one representative mouse 
after IV injection 4 h (a), 24h (b) and  48 h (c) pi. (d) Ex vivo biodistribution  48 h pi (N=4) and 92 h pi (N=4) after 
injection. The bar represent the average of uptake ± SEM.  (e-h)  SPECT/CT imaging  of one representative mouse 
after IT injection.  Focus  scan  on  the tumor region,  30 min  pi (e: maximum intensity projection , f: coronal view); 
whole body scan 24 h (g) and  48 h (h) pi. (i) Ex vivo biodistribution  48 h pi (N=4) and 72 h pi (N=4) after injection. 
The bar represent the average of uptake ± SEM. 
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Fig 3.  Comparison different injection route on critical organs uptake and TTR. (a) uptake in tumor and liver after 
111In-DTPA-P94 administration IV and IT and after IT injection of  111In-DTPA .  The bar represents the average of 
the uptake (N=4) ± SEM. (b) Tumor to tissue ratio over time after IV  or IT injection. The dots represent the 
average of uptake for each organ (N=4). 
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